The impact of comorbidities on stroke prophylaxis strategies in atrial fibrillation patients

American Journal of Therapeutics

Volumn 18, Issue 6, 2011, Pages 510-517

  Somberg, John C ^a  

^a RUSH UNIVERSITY   (United States)

Author keywords

anticoagulant; atrial fibrillation; comorbidities; stroke

Indexed keywords

ACETYLSALICYLIC ACID; ANTIVITAMIN K; APIXABAN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DABIGATRAN ETEXILATE; DIGOXIN; DRONEDARONE; EDOXABAN; ENALAPRIL; PLACEBO; RIVAROXABAN; TRANDOLAPRIL; WARFARIN;

ANTICOAGULANT THERAPY; ARTICLE; BRAIN ISCHEMIA; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; DIABETES MELLITUS; DRUG SAFETY; HEART ATRIUM FIBRILLATION; HEART FAILURE; HIGH RISK PATIENT; HUMAN; MORTALITY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RISK ASSESSMENT; STROKE; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK;

ANTICOAGULANTS; ANTITHROMBINS; ATRIAL FIBRILLATION; CHEMOPREVENTION; COMORBIDITY; DIABETES MELLITUS; FACTOR XA; FIBRINOLYTIC AGENTS; HEART FAILURE; HUMANS; RISK FACTORS; STROKE; VITAMIN K;

EID: 81755161395     PISSN: 10752765     EISSN: 15363686     Source Type: Journal    
DOI: 10.1097/MJT.0b013e31823778db     Document Type: Article

References (48)

1. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the management of patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006;114:E257-E354. (Pubitemid 44252297)
2. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285:2370-2375. (Pubitemid 32424106)
3. Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006;114:119-125. (Pubitemid 44420743)
4. Fendrick AM. A pharmacoeconomic perspective on stroke prevention in atrial fibrillation. Am J Manag Care. 2010;16:S284-S290.
5. Schnabel RB, Sullivan LM, Levy D, et al. Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study. Lancet. 2009;373:739-745.
6. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31:2369-2429.
7. Naccarelli GV, Varker H, Lin J, et al. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol. 2009;104:1534-1539.
8. Wang TJ, Parise H, Levy D, et al. Obesity and the risk of new-onset atrial fibrillation. JAMA. 2004;292:2471-2477. (Pubitemid 39552671)
9. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983-988.
10. Medi C, Hankey GJ, Freedman SB. Stroke risk and antithrombotic strategies in atrial fibrillation. Stroke. 2010; 41:2705-2713.
11. Padeletti L, Pieragnoli P, Jentzen V, et al. The comorbidity of atrial fibrillation and heart failure: a challenge for electrical therapies. Eur Heart J. 2007;9:I81-I86.
12. Mechcatie E. Dronedarone permanent AF study stopped due to CV event imbalance. Elsevier Global Medical News. Available at: http://infoviewer.biz/ infodisplay/story/imn070820111817216346.html?APP=7&CU=imn5804.Accessed August 1, 2011.
13. Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347:1825-1833. (Pubitemid 35417773)
14. Van Gelder IC, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;347:1834-1840. (Pubitemid 35417774)
15. Roy D, Talajic M, Nattel S, et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med. 2008;358:2667-2677. (Pubitemid 351860859)
16. Nasr IA, Bouzamondo A, Hulot JS, et al. Prevention of atrial fibrillation onset by beta-blocker treatment in heart failure: a meta-analysis. Eur Heart J. 2007;28:457-462. (Pubitemid 47343566)
17. Goldstein LB, Bushnell CD, Adams RJ, et al. Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/ American Stroke Association. Stroke. 2011;42:517-584.
18. Jun M, Foote C, Lv J, et al. Effects of fibrates on cardiovascular outcomes: a systematic review and metaanalysis. Lancet. 2010;375:1875-1884.
19. Ducharme A, Schiffrin EL. Reviewing the future of reninangiotensin system blockade: the role of angiotensinconverting enzyme inhibitors and angiotensin receptor blockers in the prevention of atrial fibrillation. Can J Cardiol. 2010;26(suppl E):21E-23E.
20. Levy S. Drug Insight: angiotensin-converting-enzyme inhibitors and atrial fibrillation-indications and contraindications. Nat Clin Pract Cardiovasc Med. 2006;3:220-225.
21. Bernstein RA, Passman R. Prevention of stroke in patients with high-risk atrial fibrillation. Curr Neurol Neurosci Rep. 2010;10:34-39.
22. Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285:2864-2870. (Pubitemid 32537350)
23. Singer DE, Albers GW, Dalen JE, et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133:546S-592S. (Pubitemid 351892972)
24. Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest. 2010;137:263-272.
25. Gage BF, van Walraven C, Pearce L, et al. Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation. 2004;110:2287-2292. (Pubitemid 39407328)
26. Lip GY, Halperin JL. Improving stroke risk stratification in atrial fibrillation. Am J Med. 2010;123:484-488.
27. Baruch L, Gage BF, Horrow J, et al. Can patients at elevated risk of stroke treated with anticoagulants be further risk stratified? Stroke. 2007;38:2459-2463. (Pubitemid 47329622)
28. Poli D, Antonucci E, Grifoni E, et al. Stroke risk in atrial fibrillation patients on warfarin. Predictive ability of risk stratification schemes for primary and secondary prevention. Thromb Haemost. 2009;101:367-372.
29. Ogilvie IM, Newton N,Welner SA, et al. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med. 2010;123:638-645.
30. Nieuwlaat R, Olsson SB, Lip GY, et al. Guideline-adherent antithrombotic treatment is associated with improved outcomes compared with undertreatment in high-risk patients with atrial fibrillation. The Euro Heart Survey on Atrial Fibrillation. Am Heart J. 2007;153:1006-1012. (Pubitemid 46823965)
31. EckmanMH, SingerDE, Rosand J, et al.Moving the tipping point: the decision to anticoagulate patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2011;4:14-21.
32. Hirsh J, Guyatt G, Albers GW, et al. Executive summary: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133: 71S-109S. (Pubitemid 351892961)
33. Connolly SJ, Pogue J, Hart RG, et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med. 2009;360:2066-2078.
34. Wann LS, Curtis AB, January CT, et al. 2011 ACCF/ AHA/HRS focused update on the management of patients with atrial fibrillation (Updating the 2006 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2011;57:223-242.
35. Bereznicki LR, Peterson GM. New antithrombotics for atrial fibrillation. Cardiovasc Ther. 2010;28:278-286.
36. Ezekowitz MD, Levine JA. Preventing stroke in patients with atrial fibrillation. JAMA. 1999;281:1830-1835. (Pubitemid 29231134)
37. Upshur RE, Papoushek C,Macdonald D, et al. Short report: managing anticoagulation. Comparison of results at three primary care centres. Can Fam Physician. 2003;49:181-184. (Pubitemid 36231006)
38. United States Food and Drug Administration. FDA approves Pradaxa to prevent stroke in people with atrial fibrillation [press release]. Available at: http://www.fda.gov.NewsEvents/Newsroom/PressAnnouncements/ucm230241.htm. Accessed October 19, 2010.
39. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-1151.
40. O'Riordan M. Off orbit ROCKET AF: rivaroxaban noninferior to warfarin, but superiority analyses at odds. Am Heart Assoc. Available at: http://www.theheart.org/article/1148785.do. Accessed September 13, 2011.
41. Connolly SJ, Eikelboom J, Flaker G, et al. AVERROES: apixaban versus acetylsalicylic acid (ASA) to prevent strokes. Eur Soc Cardiol. Available at: http://www.escardio.org/congresses/esc-2010/congress-reports/Pages/ 708-3-AVERROES.aspx. Accessed December 26,2010.
42. Chung N, Jeon HK, Lien LM, et al. Safety of edoxaban, an oral factor Xa inhibitor, in Asian patients with nonvalvular atrial fibrillation. Thromb Haemost. 2011;105: 535-544.
43. Weitz JI, Connolly SJ, Patel I, et al. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost. 2010;104:633-641.
44. Ruff CT, Giugliano RP, Antman EM, et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor x. A next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J. 2010;160:635-641.
45. Stangier J, Stahle H, Rathgen K, et al. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet. 2008;47:47-59. (Pubitemid 350260888)
46. Schwartz NE, Albers GW. Dabigatran challenges warfarin's superiority for stroke prevention in atrial fibrillation. Stroke. 2010;41:1307-1309.
47. Wong PC, Crain EJ, Xin B, et al. Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies. J Thromb Haemost. 2008;6:820-829. (Pubitemid 351524543)
48. Patel MR. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J. 2010;159:340-347.